Cargando…
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. SUPPLEMENTARY INFORMATI...
Autores principales: | Vu, Tuan, Meisel, Andreas, Mantegazza, Renato, Annane, Djillali, Katsuno, Masahisa, Aguzzi, Rasha, Enayetallah, Ahmed, Beasley, Kathleen N., Rampal, Nishi, Howard, James F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444731/ https://www.ncbi.nlm.nih.gov/pubmed/37351816 http://dx.doi.org/10.1007/s40120-023-00514-4 |
Ejemplares similares
-
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
por: Vu, Tuan, et al.
Publicado: (2023) -
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension
por: Meisel, Andreas, et al.
Publicado: (2023) -
Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
por: Vu, Tuan, et al.
Publicado: (2023) -
Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023) -
Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)